Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC Study Shows Limited Risk Statement Works, But Will Pharma Ad Practices Change?

Executive Summary

Viewers retain more risks and benefits in DTC ads showing only limited risk information, but experts predict it may not result in substantial change right away.

You may also be interested in...

TV Drug Ads: FDA May Pursue Further Research Before Policy Changes

US agency's study found that mentioning fewer risks in direct-to-consumer ads helped with recall and in some cases with recognition but led viewers to say they didn’t have enough information.

Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More

Sponsors and payers question guidances' scope and potential audiences, and wonder if the agency couldn't just perform some retrospective audits of off-label communication to speed things up.

DTC Ad Risk Disclosures Could Be Limited To ‘Serious And Actionable’

Despite PhRMA’s concerns, FDA is proceeding with a study using modified versions of existing TV ads, but agency will revise study questions to focus on value of the ‘major statement’ and not other aspects of ads.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts